MC1R agonist (α-MSH analogue)
Melanotan-1 (afamelanotide related)
Linear α-MSH analogue that stimulates MC1R-dependent eumelanin synthesis. Afamelanotide is the licensed implant relative in photodermatoses in some regions.
Primary Mechanism of Action
Clinical / Scientific
Melanotan-1 / afamelanotide analogues activate MC1R on melanocytes, increasing eumelanin. Licensed afamelanotide implants exist for selected photodermatoses; unregulated “tanning peptides” are not those products.
Pathway Targets
MC1 receptor
Scientific explanation
Melanogenesis agonism.
Pathway Convergence
Clinical / Scientific
Target → pathway → downstream effect → biological consequence. This is a mechanistic map, not a treatment claim.
Receptor to physiology
Target to downstream effect: MC1 receptor
Mechanistically Relevant Repurposed & Adjunctive Applications
Erythropoietic protoporphyria (afamelanotide implant, labelled markets)
EstablishedMechanistic rationale
Afamelanotide is labelled in some regions. Catalog “Melanotan 1” research vials are not that implant.
Mechanistic Application Matrix
| Biological Target | Mechanism | Potential Relevance | Evidence Level |
|---|---|---|---|
| MC1R | Agonism | Eumelanin synthesis | Established mechanism |
In Plain Language
Melanotan-1 copies the tanning hormone’s message at MC1 receptors so pigment cells make more eumelanin.
Compounds Sharing Pathways
Other library compounds whose structured pathway data overlap this ingredient. Shared pathways are not combination recommendations.
MC1 receptor
Mechanistic information is provided for scientific and educational purposes. Discussion of biological pathways or investigational applications does not establish clinical efficacy or constitute individualized medical advice.